drugset / Trial / NCT04726215

Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer

NCT04726215 ↗

Phase 2 Unknown 50 enrolled CellSight Technologies, Inc.
NaSingle-groupOpen-labelDiagnostic

Summary

This is a pilot study using \[18F\]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors at multiple study sites. The main objectives of the study are to quantify the change in \[18F\]F AraG PET signal before and after CkIT therapy, and to correlate this change in \[18F\]F AraG PET signal with a radiographic response.

Timeline

Start
2021-04-15
Primary completion
2024-10-15
Completion
2024-10-15

Drugs

EvaluationDrugModalityDoseRoute
Subject F-ARAG Diagnostic / imaging agent 185 mbq —